Joachim P. Steinbach

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Wolfgang Wick, Michael Platten, Christoph Meisner et al. · The Lancet Oncology · 2012 · 1.1K citations · Full text

Medicine, Geriatric Medicine, Oncology +14

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp, Monika E. Hegi, Thierry Gorlia et al. · The Lancet Oncology · 2014 · 1K citations

Medicine, Oncology, Pharmacotherapy +14

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

Michael Weller, Jörg Felsberg, Christian Hartmann et al. · Journal of Clinical Oncology · 2009 · 611 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 576 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter

Michael Lim, Michael Weller, Ahmed Idbaïh et al. · Neuro-Oncology · 2022 · 501 citations · Full text

Medicine, Oncology, Radiation Oncology +17